In the past year clinicians have shown increasing receptivity to AI-enabled clinical functions, in part because their exposure to administrative solutions has increased their comfort with—and even outright enthusiasm for—the potential of AI more generally. These trends might seem surprising at first glance, given that the general industry commentary suggests that provider margins finally started to stabilize in 2023, and improved even further across 2024. This material (including market commentary, market data, observations or the like) has been prepared by personnel in the Investment Banking Group of JPMorgan Chase & Co. and/or its affiliates and subsidiaries worldwide (“J.P. Morgan”). It has not been reviewed, endorsed or otherwise approved by, and is not a https://dublindecor.net/plants/how-sterile-processing-technicians-impact-patient-safety-in-hospitals.html work product of, any research department of J.P.
To navigate these regulatory landscapes, PE firms often employ Management Services Organizations (MSOs). The MSO, owned by the PE firm, manages non-legal functions such as marketing and administration, while the law firm retains control over legal services. This structure enables compliance with ownership regulations while allowing PE firms to invest in the business aspects of law practices.
Investment Opportunities in the Georgian Medical Sector
Looking ahead to 2026, take-privates are poised to be a meaningful, and potentially growing, part of the deal mix. The combination of elevated public indices, uneven multiple expansion, and continued portfolio simplification may underpin activity. This activity is likely to be selective rather than broad-based, concentrated in segments where operational turnarounds, carve-outs, or digital enablement can materially shift earnings trajectories. With the hope of better economic conditions as well as reduced headwinds for many subsectors, respondents to our survey said they are looking forward to increased M&A in 2025.
Stay ahead of markets with the latest insights from the BlackRock Investment Institute.
It represents an investment arbitrage opportunity because it has historically been underinvested across private equity, venture capital, and pharma. The macroeconomic climate improved last year, seemingly setting the stage for a more productive HCLS M&A marketplace. Inflation declined, leading to an anticipation of interest rate cuts by the US Federal Reserve that then began with a large, 50-basis-point reduction in September. Consumers continued to spend, unemployment remained low, and the US avoided the recession that many economists had forecast. As portfolio optimisation continues and next-generation technologies scale, we expect medtech deal activity in 2026 to remain robust.
- The sector continues to benefit from demographic tailwinds and the shift to outpatient and home-based care.
- We explore how capital, data and risk are driving the next phase of the transition.
- In the past year clinicians have shown increasing receptivity to AI-enabled clinical functions, in part because their exposure to administrative solutions has increased their comfort with—and even outright enthusiasm for—the potential of AI more generally.
- The breakthrough demonstrates robots successfully completing fiddly tasks that many humans struggle with, such as drawing cash from a wallet and reinserting it, or carefully stacking oranges in neat pyramids.
- The cookie will expire after six months, or sooner should there be a material change to this important information.
Over a billion people living with mental health conditions – services require urgent scale-up
- Ambulatory and post-acute services are expected to drive healthcare sector volume growth in 2026, fueled by cost pressures, an aging population, advances in therapy and value-based care.
- Technology-enabled services that have developed unique or market-leading platforms are particularly attractive.
- Another possible byproduct of MFN would be more splits-rights deals, in which a company licenses EU or emerging-market rights to a partner, which could insulate U.S. pricing from downward pressure.
- Annual revenue from drugs originating in China could soar to $34 billion by 2030 and $220 billion by 2040, according to Morgan Stanley Research.
- As the two major commercialized innovators, Novo and Eli Lilly, drove very strong growth , companies across the supply chain positioned themselves to capitalize on the growth opportunities.
Biotech, however, remains uneven, and while public markets are opening for late-stage, data-rich, and derisked assets, much of the earlier-stage cohort remains constrained. M&A remains the fastest and most effective way to modernise operations, accelerate scientific and digital innovation, and build the capabilities required for prevention-led, personalised, and care-anywhere models. The deals that stand out will be those backed by differentiated data http://www.portobellocc.org/pccpn/2016/02/19/public-meetings-notice-review-of-childrens-hospital-services/ and evidence-backed innovation, AI-enhanced productivity, and clear pathways to long-term value creation.
- Healthcare leaders have key growth opportunities in 2026 despite the mounting pressures that are reshaping the industry.
- New research reveals that marketers are successfully manipulating AI search responses through strategic creation of self-serving listicles and recommendation content.
- And provider and biopharma anchored activity while healthcare IT continued to grow its share of healthcare transaction volume.
- Even so, drugmakers targeting global markets said they cannot rely on Chinese patient recruitment alone.
The firm’s bankers also spoke about how an M&A rebound could further accelerate the resurgence in IPOs. In 2024, healthcare composed 20% of total IPO volume and had the greatest number by sector. Healthcare IPOs are gaining momentum mostly in therapeutics, diagnostics and MedTech.
Life sciences dealmaking looks east
Erdei spearheaded the organization of Jefferies’ annual Global Healthcare Conference and hosts the annual Healthcare Temperature Check. Understanding how these forces interact is essential for navigating the year ahead. Get the insights that matter — grounded in data, shaped by research and focused on the themes that will define 2026. Pratik Desai, a 34-year-old technologist, developed an AI-assisted workflow in early 2026 to help manage his mother’s Stage 4 duodenal adenocarcinoma care. The system ingested daily Epic medical record exports into NotebookLM and Claude, enabling him to spot CAT-scan misdiagnoses, detect medical emergencies, and coordinate care more effectively than traditional methods. Google has fully integrated NotebookLM, its AI-powered research assistant, directly into the Gemini chatbot interface, allowing users to create research notebooks without switching between applications.
How are healthcare investors thinking about value creation over the next decade?
You acknowledge that certain information contained in this Website supplied by third parties may be incorrect or incomplete, and such information is provided on an “AS IS” basis. We reserve the right to change, modify, add, or delete, any content and the terms of use of this Website without notice. Users are advised to periodically review the contents of this Website to be familiar with any modifications.
Healthcare services: Care anywhere, scale everywhere
Despite making its LLaMA models open source and aggressively promoting AI features across its platforms, Meta has seen minimal user engagement with its AI products compared to competitors like OpenAI and Google. METATRON joins other recent AI security tools like Apex, an autonomous AI-powered penetration testing agent, and follows Kali Linux’s official integration of Claude AI for penetration testing via Model Context Protocol. These developments highlight the rapid adoption of AI in cybersecurity, where automated vulnerability discovery and threat analysis are becoming increasingly sophisticated and accessible to security professionals.
The integration represents a shift in the traditional workflow from brand → human research → marketplace → publisher to brand → AI agent → marketplace → publisher. This automation allows AI assistants to connect to marketplaces, assemble options, map them to formats and KPIs, with human teams only stepping in for strategy refinement and partnership negotiations. Anthropic has significantly expanded its compute agreement with Google and Broadcom amid exploding demand for Claude models, particularly from enterprise customers. The company’s revenue run rate has skyrocketed to $30 billion, marking a dramatic jump from $9 billion recorded at the end of 2025, despite being labeled a supply chain risk by the U.S.
Lau noted that global pharma will guide the way on dealmaking, and that markets with predictable regulation and stable interest rates will see the most activity. “The future will reward those who can execute efficiently and build trust-based, long-term relationships, especially as global competition for innovative assets intensifies,” he said. Drugmakers said they are exploring direct-to-consumer (DTC) models as a lever to lower costs while broadening access. This approach may be most viable for drugs including those for HIV and diabetes, oral GLP-1s and respiratory or inhaled medicines, compared to high-cost branded therapies that require complex financing. DTC models also align with cash-pay channels, and options for patients to secure lower prices by committing to longer treatment durations.